- Home
- MSM vs SYRE Comparison
MSM vs SYRE Comparison
Compare MSM & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSM | SYRE |
|---|---|---|
| Founded | 1941 | 2013 |
| Country | United States | United States |
| Employees | N/A | 112 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 8.0B |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MSM | SYRE |
|---|---|---|
| Price | $121.54 | $91.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $96.20 | $85.08 |
| AVG Volume (30 Days) | 505.1K | ★ 1.1M |
| Earning Date | 04-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.12 | N/A |
| Revenue | ★ $3,363,817,000.00 | N/A |
| Revenue This Year | $5.82 | N/A |
| Revenue Next Year | $5.26 | N/A |
| P/E Ratio | $39.12 | ★ N/A |
| Revenue Growth | ★ 4.99 | N/A |
| 52 Week Low | $78.80 | $15.11 |
| 52 Week High | $130.46 | $110.18 |
Technical Indicators
Market Signals| Indicator | MSM | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 45.93 |
| Support Level | $116.15 | $82.83 |
| Resistance Level | $122.92 | $92.10 |
| Average True Range (ATR) | 2.73 | 3.84 |
| MACD | 0.35 | 0.35 |
| Stochastic Oscillator | 72.98 | 68.01 |
Price Performance
Historical ComparisonAbout MSM MSC Industrial Direct Company Inc.
Founded in 1941, MSC Industrial Direct originally manufactured and sold cutting tools to metalworking shops in New York. Through a series of acquisitions and organic expansions, MSC has grown into an industrial distribution powerhouse with a focus on specialized metalworking products and services. The firm also distributes a wide breadth of maintenance, repair, and operations supplies. MSC primarily operates in North America, where it derives over 95% of its revenue.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.